Fiona Masters, MD
Adolescent Medicine · Dothan, ALNPI 1194885681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 395 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,312 and has fallen 81.7% since, to $240 in 2025. Among adolescent medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$778
- Johnson & Johnson$738
- Lilly USA, LLC$497
- AbbVie$471
- Amgen$426
- Novo Nordisk$368
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,063100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $778 |
| Johnson & Johnson | 33 | $738 |
| Lilly USA, LLC | 40 | $497 |
| AbbVie | 30 | $471 |
| Amgen | 28 | $426 |
| Novo Nordisk | 32 | $368 |
| Amarin Pharma, Inc. | 21 | $340 |
| AstraZeneca | 22 | $328 |
| Novartis | 22 | $296 |
| Bayer | 14 | $219 |
| Pfizer | 12 | $200 |
| Boehringer Ingelheim | 14 | $198 |
| Merck | 14 | $191 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $163 |
| E.r. Squibb & Sons, L.L.C. | 8 | $122 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Biohaven Pharmaceuticals, Inc. | 5 | $70 |
| Astellas Pharma US Inc | 3 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Eisai Inc. | 4 | $54 |
| Abbott | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Averitas Pharma Inc. | 1 | $22 |
| Gilead | 1 | $20 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Grifols USA, LLC | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Medtronic | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,072 in reported general payments places this provider in the 95th percentile of 28 adolescent medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $93,450 |
| MounjaroTirzepatide | 51 | $53,713 |
| EliquisApixaban | 52 | $48,347 |
| JanuviaSitagliptin Phosphate | 33 | $38,610 |
| JardianceEmpagliflozin | 32 | $33,472 |
| FarxigaDapagliflozin Propanediol | 28 | $25,083 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,947 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $14,128 |
| MyrbetriqMirabegron | 21 | $11,157 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,830 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $4,043 |
| Pitavastatin Calcium | 16 | $2,531 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $2,078 |
| Levothyroxine Sodium | 134 | $1,703 |
| FenofibrateFenofibrate Nanocrystallized | 30 | $1,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $368 | $93,45079 claims |
| Lilly USA, LLCMounjaro | $497 | $53,71351 claims |
| PfizerEliquis | $200 | $48,34752 claims |
| MerckJanuvia | $191 | $38,61033 claims |
| Boehringer IngelheimJardiance | $198 | $33,47232 claims |
| AstraZenecaFarxiga | $328 | $25,08328 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $778 | $21,77837 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $11,15721 claims |
| AbbVieSynthroid | $471 | $87120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 adolescent medicine providers in Alabama.
Other adolescent medicine in Dothan
- Kristin RagerMobile$82K
- Kristi MillerOpelika$3K
- Paul AmamooBirmingham$2K
- Bipin KumarWetumpka$2K
- Mary WellsMobile$1K
- Albert HollowayMontgomery$1K
- Debra GardnerMobile$1K
- James HarrellMobile$1K
- Jennifer QuillinHazel Green$1K
- Ellen RoyalOpelika$903
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.